Hence, the efficacy of ICI treatment may also require polyclonal CD8 T cell-mediated anti-tumor immunity; yet we lack a well-controlled model system to delineate dynamic changes in TCR repertoire and transcriptome of CD8 TILs at a single-cell resolution, with such changes correlating to differential ICI responses. Here, CD8A is linked to neoplasm.